28.05.2012 • News

Drugmaker Amylin Draws Initial Bids

Biotechnology company Amylin Pharmaceuticals has drawn initial bids from drugmakers Merck & Co and Sanofi, Bloomberg News reported on Friday, citing anonymous sources.

The drugmakers made offers of at least $25 a share, which would value Amylin at more than $4 billion, the report said.

Sources have told Reuters that Amylin, which sells the diabetes drugs Byetta and Bydureon, started reaching out to potential buyers in April.

Merck declined to comment. Amylin and Sanofi were not immediately available to comment.

 

 

 

Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Top-Feature

most read